Preferred Label : saxagliptin;

MeSH note : putative antidiabetic agent for treating type 2 diabetes; inhibits DPP4 protein, human; structure in first source;

CISMeF synonym : 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile; (S)-3-hydroxyadamantylglycine-4,5-methanoprolinenitrile trifluoroacetic acid salt; AstraZeneca brand of saxagliptin; BMS 477118; Bristol-Myers squibb brand of saxagliptin; onglyza;

MeSH synonym : 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate;

MeSH hyponym : BMS477118; BMS-477118;

MeSH CAS label : (1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl) acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile hydrate;

Is substance : O;

UNII : 9GB927LAJW;

InChIKey : AFNTWHMDBNQQPX-NHKADLRUSA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3283449/fr/komboglyze-metformine-/-saxagliptine
2021
false
false
false
France
evaluation of the transparency committee
saxagliptin
metformin
dipeptides
adamantane
metformin and saxagliptin
treatment outcome
insurance, health, reimbursement
drug combinations
Saxagliptin Hydrochloride
Metformin Hydrochloride
diabetes mellitus, type 2
hypoglycemic agents
drug therapy, combination
administration, oral
adult
incretins
dipeptidyl-peptidase iv inhibitors

---
https://www.has-sante.fr/jcms/p_3283452/fr/onglyza-saxagliptine-chlorhydrate-de
2021
false
false
false
France
evaluation of the transparency committee
saxagliptin
dipeptides
adamantane
treatment outcome
administration, oral
diabetes mellitus, type 2
Saxagliptin Hydrochloride
hypoglycemic agents
incretins
dipeptidyl-peptidase iv inhibitors
saxagliptin
drug therapy, combination
insurance, health, reimbursement

---
https://www.ema.europa.eu/en/medicines/human/EPAR/qtrilmet
2019
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
metformin
dapagliflozin
saxagliptin
Metformin Hydrochloride
Metformin Hydrochloride
hypoglycemic agents
hypoglycemic agents
drug approval
europe
metformin, saxagliptin and dapagliflozin
diabetes mellitus, type 2
adult
administration, oral
incretins
incretins
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
Glycated Hemoglobin
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
dapagliflozin
metformin
dapagliflozin
saxagliptin
dapagliflozin
dipeptides
adamantane
glucosides
benzhydryl compounds
dapagliflozin
dipeptides
glucosides
benzhydryl compounds

---
https://www.ema.europa.eu/medicines/human/EPAR/qtern
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
dapagliflozin
dapagliflozin
saxagliptin and dapagliflozin
saxagliptin
saxagliptin
adult
diabetes mellitus, type 2
administration, oral
Sodium-Glucose transporter 2
incretins
incretins
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
glucosides
benzhydryl compounds
dipeptides
adamantane
adamantane
dipeptides
adamantane

---
https://www.revmed.ch/RMS/2016/RMS-N-527/Combinaison-gliptine-gliflozine-dans-le-traitement-du-diabete-de-type-2
2016
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
drug combinations
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
treatment outcome
saxagliptin and dapagliflozin
dapagliflozin
saxagliptin
Linagliptin
linagliptin and empagliflozin
empagliflozin
Product containing empagliflozin and linagliptin (medicinal product)
administration, oral
Sodium-Glucose transporter 2
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
dipeptides
adamantane
adamantane
benzhydryl compounds
glucosides

---
http://www.has-sante.fr/portail/jcms/c_2052925/fr/onglyza
2015
false
France
French
evaluation of the transparency committee
administration, oral
saxagliptin
saxagliptin
saxagliptin
insurance, health, reimbursement
diabetes mellitus, type 2
adult
drug therapy, combination
insulin
metformin
hypoglycemic agents
treatment outcome
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
dipeptides
dipeptides
adamantane

---
http://www.has-sante.fr/portail/jcms/c_1782549/fr/komboglyze
http://www.has-sante.fr/portail/jcms/c_1782549/fr/komboglyze-saxagliptine/metformine-antidiabetique
2014
false
France
French
sulfonylurea compounds
Metformin Hydrochloride
Saxagliptin Hydrochloride
guidelines for drug use
evaluation of the transparency committee
drug combinations
saxagliptin
saxagliptin
metformin and saxagliptin
administration, oral
insurance, health, reimbursement
metformin
metformin
hypoglycemic agents
hypoglycemic agents
adult
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
adamantane
dipeptides
aged
drug therapy, combination
dipeptides
dipeptides

---
http://www.has-sante.fr/portail/jcms/c_1774614/fr/onglyza
http://www.has-sante.fr/portail/jcms/c_1774614/fr/onglyza-saxagliptine
2014
false
France
French
sulfonylurea compounds
guidelines for drug use
evaluation of the transparency committee
administration, oral
saxagliptin
saxagliptin
saxagliptin
insurance, health, reimbursement
diabetes mellitus, type 2
adult
drug therapy, combination
metformin
hypoglycemic agents
treatment outcome
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
randomized controlled trials as topic
dipeptides
dipeptides
adamantane

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=68674913
2013
summary of product characteristics
tablets
metformin
saxagliptin

---
http://www.has-sante.fr/portail/jcms/c_1241667/komboglyze
http://www.has-sante.fr/portail/jcms/c_1598723/fr/komboglyze
2013
France
French
evaluation of the transparency committee
drug combinations
saxagliptin
saxagliptin
metformin and saxagliptin
administration, oral
insurance, health, reimbursement
metformin
metformin
hypoglycemic agents
hypoglycemic agents
adult
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
adamantane
dipeptides
aged
clinical trials, phase iii as topic
risk assessment
drug therapy, combination
insulin

---
http://www.has-sante.fr/portail/jcms/c_1598714/fr/onglyza
http://www.has-sante.fr/portail/jcms/c_900487/onglyza
2013
France
French
evaluation of the transparency committee
administration, oral
saxagliptin
saxagliptin
saxagliptin
insurance, health, reimbursement
diabetes mellitus, type 2
adult
drug therapy, combination
insulin
metformin
hypoglycemic agents
treatment outcome
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
randomized controlled trials as topic
dipeptides
dipeptides
adamantane

---
https://www.ema.europa.eu/medicines/human/EPAR/Onglyza
2012
United Kingdom
French
English
syndication feed
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
adult
drug approval
drug labeling
treatment outcome
tablets
administration, oral
breast feeding
drug evaluation, preclinical
dipeptides
saxagliptin
saxagliptin
hypoglycemic agents
hypoglycemic agents
adamantane
diabetes mellitus, type 2
drug therapy, combination
drug interactions
pregnancy
saxagliptin
drug evaluation
summary of product characteristics
package leaflet

---
https://www.ema.europa.eu/medicines/human/EPAR/Komboglyze
2012
United Kingdom
English
French
drug evaluation
summary of product characteristics
package leaflet
syndication feed
dipeptides
dipeptides
adamantane
adult
drug interactions
pregnancy
breast feeding
fertility
drug evaluation, preclinical
saxagliptin
metformin
drug combinations
drug approval
treatment outcome
saxagliptin
metformin
administration, oral
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
hypoglycemic agents
hypoglycemic agents
metformin and saxagliptin

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66862731
2012
France
summary of product characteristics
package leaflet
tablets
saxagliptin

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64204535
2012
France
summary of product characteristics
package leaflet
tablets
saxagliptin

---
Summary Basis of Decision (SBD)
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00107
2010
false
Canada
English
French
saxagliptin
saxagliptin
drug approval
dipeptides
adamantane
DPP4 protein, human
dipeptidyl peptidase 4
hypoglycemic agents
hypoglycemic agents
drug combinations
canada
saxagliptin
dipeptidyl peptidase 4
drug information

---
http://www.has-sante.fr/portail/jcms/c_945968/onglyza-saxagliptine-inhibiteur-de-la-dipeptidylpeptidase-4-dpp-4
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-01/onglyza_-_ct-7111.pdf
2009
France
French
administration, oral
saxagliptin
dipeptidyl-peptidase iv inhibitors
diabetes mellitus, type 2
dipeptides
adamantane
saxagliptin
insurance, health, reimbursement
adult
drug therapy, combination
treatment outcome
saxagliptin
dipeptidyl-peptidase iv inhibitors
dipeptides
evaluation of the transparency committee
guidelines for drug use

---
Nous contacter.
24/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.